P. Minor

发表

Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome

J. Maizel, A. Cann, G. Schild, 1985, Nature.

New model for the secondary structure of the 5' non-coding RNA of poliovirus is supported by biochemical and genetic data that also show that RNA secondary structure is important in neurovirulence.

M. Skinner, G. Dunn, P. Minor, 1989, Journal of molecular biology.

Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472----U.

Y. Svitkin, P. Minor, J. Almond, 1990, Virology.

Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture.

D. Stone, R. Skuce, P. Minor, 1992, Virology.

Coding changes in the poliovirus protease 2A compensate for 5'NCR domain V disruptions in a cell-specific manner.

P. Minor, A. Macadam, G. Ferguson, 2000, Virology.

The 5' noncoding region and virulence of poliovirus vaccine strains.

D. Stone, P. Minor, J. Almond, 1994, Trends in microbiology.

Molecular biology and the control of viral vaccines.

G. Dunn, P. Minor, J. Almond, 1990, FEMS microbiology immunology.

Long-Term Excretion of Vaccine-Derived Poliovirus by a Healthy Child

W. Hall, Javier Martin, G. Dunn, 2004, Journal of Virology.

Isolation of an Intertypic Poliovirus Capsid Recombinant from a Child with Vaccine-Associated Paralytic Poliomyelitis

A. Heath, A. Lackenby, Javier Martin, 2002, Journal of Virology.

Characterization of CHAT and Cox Type 1 Live-Attenuated Poliovirus Vaccine Strains

Javier Martin, P. Minor, 2002, Journal of Virology.

Poliovirus Vaccines: Molecular Biology and Immune Response

P. Minor, J. Almond, 2002 .

Functional formation of domain V of the poliovirus noncoding region: significance of unpaired bases.

P. Minor, A. Macadam, J. Burlison, 2001, Virology.

, P D poliovirus . attenuation phenotype of Sabin type 1 Role of mutations G-480 and C-6203 in the

J. Meredith, G. Dunn, P. Minor, 1995 .

Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus

J. Meredith, G. Dunn, P. Minor, 1995, Journal of virology.

Stability of attenuated poliovirus strain genotypes in the human intestinal tract

G. Dunn, P. Minor, J. Almond, 1993 .

An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain

P. Minor, A. Macadam, G. Ferguson, 1991, Journal of virology.

The 5' noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity.

S. R. Pollard, R. Skuce, G. Dunn, 1991, Virology.

Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature

C. Christodoulou, P. Minor, A. Macadam, 1990, Journal of virology.

Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine

S. R. Pollard, G. Dunn, P. Minor, 1989, Journal of virology.

The effect of sequences in the 5' non-coding region on the replication of polioviruses in the human gut.

G. Dunn, P. Minor, 1988, The Journal of general virology.

Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine

G. Schild, M. Skinner, D. Evans, 1989, Journal of virology.

Intertypic genomic rearrangements of poliovirus strains in vaccinees.

G. Dunn, P. Minor, N. Cammack, 1988, Virology.

Studies on the attenuation of the Sabin type 3 oral polio vaccine.

G. Schild, D. Evans, G. Dunn, 1987, Journal of virological methods.

Evolution of poliovirus during an outbreak: sequential type 3 poliovirus isolates from several persons show shifts of neutralization determinants.

L. Kinnunen, A. Huovilainen, P. Minor, 1987, The Journal of general virology.

Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee.

J. Icenogle, P. Minor, A. John, 1986, The Journal of general virology.

Studies on the molecular aspects of antigenic structure and virulence of poliovirus

A. Cann, G. Schild, D. Evans, 1986 .

Comparative biochemical studies of type 3 poliovirus

P. Minor, 1980, Journal of virology.

Characterization of strains of type 3 poliovirus by oligonucleotide mapping.

P. Minor, 1982, The Journal of general virology.

Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3

D. Evans, P. Minor, J. Almond, 1983, Nature.

Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine.

A. Cann, G. Schild, D. Evans, 1984, Nucleic acids research.

Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b.

R. Mountford, G. Schild, P. Minor, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Molecular cloning of the genomes of poliovirus type 3 strains by the cDNA: RNA hybrid method

R. Mountford, G. Schild, P. Minor, 2005, Archives of Virology.

Synthesis of immunogenic, but non-infectious, poliovirus particles in insect cells by a baculovirus expression vector.

D. Bishop, M. Sullivan, P. Minor, 1989, The Journal of general virology.

Modulation of humoral response to a 12-amino-acid site on the poliovirus virion

J. Hogle, J. Icenogle, P. Minor, 1986, Journal of virology.

Antigenic structure of polioviruses of serotypes 1, 2 and 3.

J. Icenogle, D. Evans, P. Minor, 1986, The Journal of general virology.

New poliovirus vaccines: a molecular approach.

A. Cann, G. Schild, D. Evans, 1984, Vaccine.

Location and primary structure of a major antigenic site for poliovirus neutralization

A. Cann, R. Mountford, G. Schild, 1983, Nature.

Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus.

D. Filman, R. Syed, M. Chow, 1989, The EMBO journal.

The complete nucleotide sequence of a common cold virus: human rhinovirus 14.

R. Mountford, P. Minor, G. Stanway, 1984, Nucleic acids research.

Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources

G. Dunn, P. Minor, N. Cammack, 1990, Journal of medical virology.

Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains.

Javier Martin, P. Minor, Graham Crossland, 2003, The Journal of general virology.

Poliovirus-specific CD4+ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor

A. Nomoto, K. Mills, B. Mahon, 1995, The Journal of experimental medicine.

Chapter 6 Picornaviridae

P. Minor, 1987 .

Construction of poliovirus intertypic recombinants by use of cDNA

G. Schild, D. Evans, G. Dunn, 1986, Journal of virology.

Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3.

G. Schild, D. Evans, P. Minor, 1985, Virology.

Live attenuated vaccines: Historical successes and current challenges.

P. Minor, 2015, Virology.

Population‐based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40

N. Andrews, W. Knowles, P. Minor, 2003, Journal of medical virology.

Genetically Thermo-Stabilised, Immunogenic Poliovirus Empty Capsids; a Strategy for Non-replicating Vaccines

P. Minor, A. Macadam, Helen Fox, 2017, PLoS pathogens.

Review and Assessment of Poliovirus Immunity and Transmission: Synthesis of Knowledge Gaps and Identification of Research Needs

M. Pallansch, K. Thompson, P. Wright, 2013, Risk analysis : an official publication of the Society for Risk Analysis.

The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3.

D. Evans, G. Dunn, P. Minor, 1989, The Journal of general virology.

Mitochondrial DNA and retroviral RNA analyses of archival oral polio vaccine (OPV CHAT) materials: evidence of macaque nuclear sequences confirms substrate identity.

G. Schild, Javier Martin, P. Minor, 2005, Vaccine.

Vaccine safety: Analysis of oral polio vaccine CHAT stocks

G. Schild, P. Minor, D. Wood, 2001, Nature.

A global regulatory science agenda for vaccines.

K. Cichutek, A. Kato, Xuguang Li, 2013, Vaccine.

Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines.

A. Coombes, S. Davis, E. Lavelle, 1999, Vaccine.

Biologicals, Including Vaccines

P. Minor, T. Sesardic, 2019, The History of Alternative Test Methods in Toxicology.

An approach to the control of disease transmission in pig‐to‐human xenotransplantation

A. Osterhaus, D. Onions, D. Cooper, 2000, Xenotransplantation.

Vaccines, Crohn's disease and autism

P. Minor, M. Afzal, 2002, Molecular Psychiatry.

Comparison of single radial immunodiffusion, SDS-PAGE and HPLC potency assays for inactivated influenza vaccines shows differences in ability to predict immunogenicity of haemagglutinin antigen.

R. Penn, O. Engelhardt, J. Wood, 2018, Vaccine.

A novel cytopathic microtitre plate assay for hepatitis A virus and anti-hepatitis A neutralizing antibodies.

J. Saldanha, P. Minor, L. Beales, 1996, Journal of virological methods.

Aerosol measles vaccination in macaques: preclinical studies of immune responses and safety.

C. Witham, T. Kuiken, A. Osterhaus, 2006, Vaccine.

Natural infection and transmission of SV40.

G. Dunn, P. Minor, P. Pipkin, 2003, Virology.

Studies of neutralising antibodies to SV40 in human sera

W. Knowles, P. Minor, P. Pipkin, 2003, Journal of medical virology.

Examination of poliovirus vaccine preparations for SV40 sequences.

P. Minor, D. Sangar, D. Wood, 1999, Biologicals : journal of the International Association of Biological Standardization.

Lack of serologic evidence for prevalent simian virus 40 infection in humans.

R. Garcea, D. Galloway, P. Minor, 2004, Journal of the National Cancer Institute.

Potential use of new poliomyelitis vaccines: memorandum from a WHO meeting.

V. Agol, S. Lemon, D. Henderson, 1990, Bulletin of the World Health Organization.

the WHO Working Group on International Reference Materials for the Diagnosis and Study of Transmissible Spongiform Encephalopathies

J. Newham, C. Bergeron, M. Vey, 2004 .

Human Papillomavirus Antibody Reference Reagents for Use in Postvaccination Surveillance Serology

J. Dillner, E. Unger, S. Beddows, 2012, Clinical and Vaccine Immunology.

WHO Expert Committee on Biological Standardization.

P. Minor, T. Burnouf, A. Padilla, 2004, World Health Organization technical report series.

Instant RNA isolation from virus-infected tissue culture fluid for the polymerase chain reaction.

P. Minor, M. Afzal, 1994, Vaccine.

Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.

R. Schwartz, O. Engelhardt, J. Heldens, 2009, Vaccine.

Investigation of porcine circovirus contamination in human vaccines.

Javier Martin, P. Minor, N. Berry, 2012, Biologicals : journal of the International Association of Biological Standardization.

Antigen chimaeras of poliovirus as potential new vaccines

G. Dunn, P. Minor, J. Almond, 1988, Nature.

An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies

R. Weiss, J. Meredith, J. McKeating, 1989, Nature.

Considerations for setting the specifications of vaccines

P. Minor, 2012, Expert review of vaccines.

Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production.

P. Minor, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Assaying the Potency of Influenza Vaccines

P. Minor, 2015, Vaccines.

WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community

G. Mattiuzzo, P. Minor, I. Knezevic, 2021, The Lancet Microbe.

Regulatory Issues in the Use of DNA Vaccines

P. Minor, 1995, Annals of the New York Academy of Sciences.

Human immunodeficiency virus and AIDS: challenges and progress

G. Schild, P. Minor, P. Minor, 1990, The Lancet.

Effect of Formaldehyde Inactivation on Poliovirus

Javier Martin, D. Eastwood, G. Dunn, 2014, Journal of Virology.

Continued use of poliovirus after eradication: hyper‐attenuated strains as a safe alternative for release testing of human immunoglobulins

J. Modrof, M. Farcet, T. Kreil, 2018, Transfusion.

Hepatitis and Polio Vaccines

P. Minor, F. Schödel, 1999 .

Isolation of Vaccine-Like Poliovirus Strains in Sewage Samples From the United Kingdom

Javier Martin, C. Anscombe, P. Minor, 2018, The Journal of infectious diseases.

Isolation of vaccine-like poliovirus strains in sewage samples from the UK

C. Anscombe, P. Minor, D. Allen, 2017 .

IDENTIFICATION OF THE ORIGIN OF POLIOVIRUS ISOLATES Report of World Health Organisation informal meetings 1979-80

G. Schild, P. Minor, 1981, The Lancet.

Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget's disease.

I. Reid, J. Cornish, K. Callon, 2008, The Journal of clinical endocrinology and metabolism.

Comparison of platform technologies for assaying antibody to Ebola virus

G. Mattiuzzo, M. Hassall, P. Minor, 2017, Vaccine.

Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes.

R. Linkins, P. Minor, D. Magrath, 1995, Bulletin of the World Health Organization.

The influence of the host cell on standardisation of influenza vaccine potency.

J. Wood, J. Robertson, P. Minor, 1999, Developments in biological standardization.

Genetic basis of attenuation of the Sabin oral poliovirus vaccines.

D. Stone, P. Minor, J. Almond, 1993, Biologicals : journal of the International Association of Biological Standardization.

Vaccines: Past, Present and Future

G. Schild, P. Minor, M. Corbel, 1999 .

Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding

D. Lublin, D. Lublin, P. Minor, 1995, Journal of virology.

Establishment of the 1st WHO International Standard for anti-EV71 serum (Human).

Javier Martín, Junzhi Wang, Zhenglun Liang, 2018, Biologicals : journal of the International Association of Biological Standardization.

Growth assay and purification of picornaviruses

P. Minor, 1985 .

Monoclonal antibodies which block cellular receptors of poliovirus.

G. Schild, D. Hockley, P. Minor, 1984, Virus research.

Human coronavirus 229E encodes a single ORF4 protein between the spike and the envelope genes

B. Berkhout, K. Pyrć, L. van der Hoek, 2006, Virology Journal.

High resolution identity testing of inactivated poliovirus vaccines

Javier Martin, P. Minor, E. Mee, 2015, Vaccine.

Eradication and cessation of programmes Vaccination and public health care

P. Minor, 2002 .

Gaps in scientific knowledge for the post eradication world.

P. Minor, 2006, Biologicals : journal of the International Association of Biological Standardization.

Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine.

J. Modlin, G. Dunn, P. Minor, 1993, The Journal of infectious diseases.

Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom.

M. Pallansch, J. Winkelstein, R. Sutter, 2004, Bulletin of the World Health Organization.

Interruption of poliovirus transmission in Ghana: molecular epidemiology of wild-type 1 poliovirus isolated from 1995 to 2008.

Javier Martin, G. Dunn, P. Minor, 2012, The Journal of infectious diseases.

Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man

D. Pillay, R. Thompson, C. MacLennan, 2004, The Lancet.

Live-attenuated strains of improved genetic stability.

J. Meredith, D. Stone, P. Minor, 2001, Developments in biologicals.

Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies.

P. Minor, 2001, Developments in biologicals.

Development of working reference materials for clinical virology.

W. Carman, P. Minor, M. Ferguson, 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Isolation of SV40 from the environment of a colony of cynomolgus monkeys naturally infected with the virus.

R. Girones, S. Bofill-Mas, P. Minor, 2004, Virology.

Potency Assay of Inactivated Influenza and Poliovaccine

R. Webster, G. Schild, J. Wood, 1988 .

Novel Parvovirus and Related Variant in Human Plasma

E. Delwart, A. Kapoor, P. Minor, 2006, Emerging infectious diseases.

Absence of chicken myelin basic protein residues in commercial formulations of MMR vaccine.

P. Minor, P. Pipkin, M. Afzal, 2000, Vaccine.

Detection of persistent measles virus infection in Crohn's disease: current status of experimental work

P. Minor, S. Ghosh, D. Wilson, 2001, Gut.

An improved immunoblotting procedure for the detection of antibodies against HIV.

A. J. Garrett, C. Bird, R. Thorpe, 1987, Journal of virological methods.

Measles virus and Crohn’s disease

P. Minor, S. Ghosh, M. Afzal, 1999, Gut.

Measles vaccination as a risk factor for inflammatory bowel disease

K. Calman, David Miller, T. MacDonald, 1995, The Lancet.

Comparison of the nucleotide and deduced amino acid sequences of the structural protein genes of the yellow fever 17DD vaccine strain from Senegal with those of other yellow fever vaccine viruses.

A. Barrett, P. Minor, J. Whitby, 1993, Vaccine.

Mumps vaccines and meningitis

P. Minor, N. Begg, T. Forsey, 1992, The Lancet.

Antigenic structure of poliovirus in inactivated vaccines.

P. Minor, M. Ferguson, D. Wood, 1993, The Journal of general virology.

Scientific consultation on the safety and containment of new poliovirus strains for vaccine production, clinical/regulatory testing and research. Report of a meeting held at NIBSC, Potters Bar, Hertfordshire, UK, 6/7th July 2016.

P. Minor, B. Lane, South Mimms, 2017, Biologicals : journal of the International Association of Biological Standardization.

Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication.

P. Minor, 2009, Vaccine.

Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains

G. Dunn, P. Minor, M. Ramsay, 2005, Journal of medical virology.

Primer extension dideoxy chain termination nucleotide sequencing of partially purified RNA virus genomes: a technique for investigating low titre viruses with extensive genome secondary structure.

A. Barrett, L. Dunster, M. Bouloy, 1990, Journal of virological methods.

Clinical safety issues of measles, mumps and rubella vaccines.

G. Schild, P. Minor, M. Afzal, 2000, Bulletin of the World Health Organization.

Evaluation of the neurovirulence test for mumps vaccines.

P. Minor, S. Marsden, P. Pipkin, 1999, Biologicals : journal of the International Association of Biological Standardization.

Bovine spongiform encephalopathy and biological products for human use. Report of an informal meeting held at NIBSC on 16 May 1988.

P. Minor, 1990, Biologicals : journal of the International Association of Biological Standardization.

3 – Location and Sequence of a Critical Antigenic Site on VP1 of Poliovirus Type 3 and Its Relevance to the Development of Novel Vaccines against Poliomyelitis

G. Schild, D. Evans, P. Minor, 1984 .

Poliomyelitis — epidemiology, molecular biology and immunology

G. Schild, O. Kew, P. Minor, 1982, Nature.

Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma.

P. Minor, S. Baylis, Nita Shah, 2004, Journal of virological methods.

Role for poliovirus protease 2A in cap independent translation.

D. Stone, P. Minor, J. Almond, 1994, The EMBO journal.

The RNAs of defective-interfering influenza virus.

R. Avery, N. Dimmock, P. Minor, 1978, Virology.

Immunochemical studies of polioviruses: identification of immunoreactive virus capsid polypeptides.

R. Thorpe, G. Schild, P. Minor, 1982, The Journal of general virology.

Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961.

M. Carbone, Rochelle Cutrone, M. Bocchetta, 2005, Cancer research.

Genetic variation among strains of wild-type yellow fever virus from Senegal.

A. Barrett, E. Wang, H. Wang, 1997, The Journal of general virology.

Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine.

A. Barrett, E. Wang, P. Minor, 1995, The Journal of general virology.

Antigenic structure of chimeras of type 1 and type 3 polioviruses involving antigenic sites 2, 3 and 4.

G. Dunn, P. Minor, J. Almond, 1991, The Journal of general virology.

Antigenic structure of chimeras of type 1 and type 3 poliovirus involving antigenic site 1.

G. Dunn, P. Minor, J. Almond, 1990, The Journal of general virology.

Conservation in vivo of protease cleavage sites in antigenic sites of poliovirus.

A. Huovilainen, P. Minor, T. Hovi, 1987, The Journal of general virology.

Report of a collaborative study for assessing the potency of hepatitis B vaccines.

A. Heath, P. Minor, M. Ferguson, 1990, Biologicals : journal of the International Association of Biological Standardization.

Antigenic and molecular properties of type 3 poliovirus responsible for an outbreak of poliomyelitis in a vaccinated population.

G. Schild, D. Evans, P. Minor, 1986, The Journal of general virology.

The 1st International Standard for anti-measles serum.

A. Heath, P. Minor, T. Forsey, 1991, Biologicals : journal of the International Association of Biological Standardization.

An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication.

P. Minor, 2016, Methods in molecular biology.

The polio endgame

P. Minor, 2014, Human vaccines & immunotherapeutics.

Environmental Surveillance Reveals Complex Enterovirus Circulation Patterns in Human Populations

M. Fernandez-Garcia, Javier Martin, G. Mujtaba, 2018, Open forum infectious diseases.

Development of Lentivirus-Based Reference Materials for Ebola Virus Nucleic Acid Amplification Technology-Based Assays

Kirsty MacLellan-Gibson, G. Mattiuzzo, P. Minor, 2015, PloS one.

WHO collaborative study to assess the suitability of an interim standard for antibodies to Ebola virus

E. Postnikova, R. Tedder, W. Hogrefe, 2016 .

Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.

G. Schild, D. Evans, P. Minor, 1985, The Journal of general virology.

Differences in conformation of type 3 poliovirus antigenic sites on non-infectious empty particles and infectious virus.

P. Minor, M. Ferguson, 1990, The Journal of general virology.

Attenuation and reversion of the Sabin vaccine strains of poliovirus.

P. Minor, 1993, Developments in biological standardization.

The molecular biology of poliovaccines.

P. Minor, 1992, The Journal of general virology.

Testing Plasma Pools for Markers of Viral Contamination: The UK Experience

A. J. Garrett, R. Thorpe, P. Minor, 1996, Vox Sanguinis.

Are recombinant products really infection risk free?

P. Minor, 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

Are recombinant products really infection risk free

P. Minor, 2001 .

Working Standards for Hepatitis B Surface Antigen for Use in the UK Blood Transfusion Service: Results of a Collaborative Study

A. Heath, P. Minor, M. Ferguson, 1993, Vox sanguinis.

The nucleotide sequence of human rhinovirus 1B: molecular relationships within the rhinovirus genus.

P. Minor, G. Stanway, P. Hughes, 1988, The Journal of general virology.

The complete nucleotide sequence of a common cold virus: human rhinovlrus 14

R. Mountford, P. Minor, G. Stanway, 1984 .

Species differences in the cerebellar distribution of six members of the Kv1 channel subfamily

C. Knowles, P. Minor, Joanne E Martin, 2020, bioRxiv.

Comparing viral metagenomics methods using a highly multiplexed human viral pathogens reagent

E. Delwart, P. Minor, Xutao Deng, 2014, Journal of Virological Methods.

Assessing the significance of reverse transcriptase activity in chick cell-derived vaccines.

G. Schild, G. Dunn, P. Minor, 1997, Biologicals (Print).

Examination of the envelope glycoprotein of yellow fever vaccine viruses with monoclonal antibodies.

D. J. Groves, A. Barrett, P. Minor, 1989, Vaccine.

Development of a candidate reference material for adventitious virus detection in vaccine and biologicals manufacturing by deep sequencing

Raju V. Misra, S. Gharbia, B. Ottenwälder, 2015, Vaccine.

Nearly Constant Shedding of Diverse Enteric Viruses by Two Healthy Infants

E. Delwart, P. Minor, Beatrix Kapusinszky, 2012, Journal of Clinical Microbiology.

Poliovirus-spectfic CD4 + Thl Clones with BothCytotoxic and Helper Activity Mediate ProtectiveHumoral Immunity against a Lethal PoliovirusInfection in Transgenic Mice Expressing the HumanPoliovirus Receptor

A. Nomoto, K. Mills, B. Mahon, 1995 .

The polio-eradication programme and issues of the end game.

P. Minor, 2012, The Journal of general virology.

Studies on the genetic basis of attenuation of the Sabin type 3 poliovirus vaccine.

G. Schild, M. Skinner, D. Evans, 1987, Biochemical Society symposium.

The coupling of transcription from influenza virions to translationin vitro

N. Dimmock, P. Minor, 2005, Archives of Virology.

Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in the mumps Urabe vaccine strain.

P. Yates, P. Minor, M. Afzal, 1998, The Journal of infectious diseases.

Antigenic and genetic variation of the HN protein of mumps virus strains.

P. Yates, P. Minor, M. Afzal, 1996, The Journal of general virology.

Matrix protein gene sequence of vaccine and vaccine-associated strains of mumps virus.

P. Yates, P. Minor, M. Afzal, 1994, The Journal of general virology.

Differentiation of vaccine and wild mumps viruses using the polymerase chain reaction and dideoxynucleotide sequencing.

P. Yates, P. Minor, T. Forsey, 1990, The Journal of general virology.

Attenuation of virulence of flaviviruses following passage in HeLa cells.

J. Stephenson, A. Barrett, L. Dunster, 1990, The Journal of general virology.

Assessment of mumps virus growth on various continuous cell lines by virological, immunological, molecular and morphological investigations.

R. Fleck, V. Dussupt, G. Stacey, 2005, Journal of virological methods.

Alternatives to Animal Testing in the Quality Control of Immunobiologicals: Current Status and Future Prospects

Bart Rombaut, Klaus Cussler, Bernward Garthoff, 1994 .

A hybridoma cell line secreting antibody to poliovirus type 3 D-antigen: detection in virus harvest of two D-antigen populations.

P. Yates, G. Schild, P. Minor, 1981, Journal of General Virology.

Selective inhibition of influenza virus protein synthesis by inhibitors of DNA function.

N. Dimmock, P. Minor, 1977, Virology.

Inhibition of synthesis of influenza virus proteins: evidence of two host-cell-dependent events during multiplication.

N. Dimmock, P. Minor, 1975, Virology.

Influence of the host cell on proteins synthesized by different strains of influenza virus.

N. Dimmock, P. Minor, J. Hart, 1979, Virology.

The multiplication of influenza virus in enucleated BHK cells fused with chicken erythrocytes.

N. Dimmock, P. Minor, 1976, Virology.

Effect of formaldehyde inactivation on poliovirus 1 2

Javier Martin, D. Eastwood, G. Dunn, 2014 .

Simian cytomegalovirus and contamination of oral poliovirus vaccines.

P. Minor, S. Baylis, N. Berry, 2003, Biologicals : journal of the International Association of Biological Standardization.

Reactivity of anti-peptide and anti-poliovirus type 3 monoclonal antibodies with synthetic peptides.

S. Reed, P. Minor, M. Ferguson, 1986, The Journal of general virology.

MONOCLONAL ANTIBODIES SPECIFIC FOR THE SABIN VACCINE STRAIN OF POLIOVIRUS 3

G. Schild, P. Minor, D. Magrath, 1982, The Lancet.

The preparation of specific immune sera against type 3 poliovirus D-antigen and C-antigen and the demonstration of two C-antigenic components in vaccine strain populations.

G. Schild, J. Wood, P. Minor, 1980, The Journal of general virology.

Immunoassay of poliovirus antigens by single-radial-diffusion: development and characteristics of a sensitive autoradiographic zone size enhancement (ZE) technique.

G. Schild, J. Wood, P. Minor, 1980, The Journal of general virology.

Ensuring safety and consistency in cell culture production processes: viral screening and inactivation.

P. Minor, 1994, Trends in biotechnology.

The complete nucleotide sequence of coxsackievirus A21.

P. Minor, G. Stanway, P. Hughes, 1989, The Journal of general virology.

A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology.

A. Heath, P. Minor, J. Fryer, 2016, Biologicals : journal of the International Association of Biological Standardization.

The nucleotide sequence of poliovirus type 3 leon 12 a1b: comparison with poliovirus type 1.

A. Cann, R. Mountford, G. Schild, 1983, Nucleic acids research.

Medicinal and other products and human and animal transmissible spongiform encephalopathies: memorandum from a WHO meeting.

A. Aguzzi, H. Budka, J. Wilesmith, 1997, Bulletin of the World Health Organization.

WHO Working Group on Technical Specifications for Manufacture and Evaluation of Yellow Fever Vaccines, Geneva, Switzerland, 13–14 May 2009

A. Barrett, P. Minor, M. Ferguson, 2010, Vaccine.

Colchicine resistance in mammalian cell lines.

D. Roscoe, P. Minor, 1975, Journal of cell science.

Detection of bovine viral diarrhoea virus nucleic acid, but not infectious virus, in bovine serum used for human vaccine manufacture.

P. Minor, M. Laassri, K. Chumakov, 2018, Biologicals : journal of the International Association of Biological Standardization.

Evolution of the Sabin Strain of Type 3 Poliovirus in an Immunodeficient Patient during the Entire 637-Day Period of Virus Excretion

Javier Martin, G. Dunn, P. Minor, 2000, Journal of Virology.

Identification of envelope protein epitopes that are important in the attenuation process of wild-type yellow fever virus

A. Barrett, L. Dunster, M. Wills, 1992, Journal of virology.

Testing of blood for antibodies to hepatitis C virus--implications for plasma pools used in the preparation of blood products.

P. Minor, 1991, Biologicals : journal of the International Association of Biological Standardization.

Rational Design of Genetically Stable, Live-Attenuated Poliovirus Vaccines of All Three Serotypes: Relevance to Poliomyelitis Eradication

J. Meredith, D. Stone, P. Minor, 2006, Journal of Virology.

A collaborative study to establish the 1st WHO International Standard for Epstein-Barr virus for nucleic acid amplification techniques.

A. Heath, P. Minor, Dianna E. Wilkinson, 2016, Biologicals : journal of the International Association of Biological Standardization.

Clustering of mumps virus isolates by SH gene sequence only partially reflects geographical origin

A. Heath, P. Minor, M. A. Afzal, 1997, Archives of Virology.

Comparison of the nucleotide sequence of the SH gene and flanking regions of mumps vaccine virus (Urabe strain) grown on different substrates and isolated from vaccinees.

P. Turner, P. Minor, T. Forsey, 1991, The Journal of general virology.

Cellular and humoral immune responses to poliovirus in mice: a role for helper T cells in heterotypic immunity to poliovirus.

K. Mills, B. Mahon, P. Minor, 1991, The Journal of general virology.

Report of the international conference on next generation sequencing for adventitious virus detection in biologicals.

Arifa S Khan, Luca Benetti, Johannes Blumel, 2018, Biologicals : journal of the International Association of Biological Standardization.

Incidence of Hepatitis C Virus RNA in Anti‐HCV‐Negative Plasma Pools and Blood Products

J. Saldanha, P. Minor, 1996, Vox sanguinis.

Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative

Javier Martin, G. Dunn, P. Minor, 2015, PLoS pathogens.

Characterisation of L cells expressing the human poliovirus receptor for the specific detection of polioviruses in vitro.

P. Minor, V. Racaniello, D. Wood, 1993, Journal of virological methods.

Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.

E. Wimmer, H. Schuitemaker, J. Cello, 2015, Vaccine.

Collaborative Study to Evaluate the Proposed 1st WHO International Standard for Human Cytomegalovirus (HCMV) for Nucleic Acid Amplification (NAT)-Based Assays

A. Heath, P. Minor, Rob Anderson, 2010 .

Decay‐accelerating factor CD55 is identified as the receptor for echovirus 7 using CELICS, a rapid immuno‐focal cloning method.

P. Minor, J. Almond, P. Pipkin, 1994, The EMBO journal.

Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines.

L. Duffy, H. Faden, P. Minor, 1991, The Journal of infectious diseases.

Collaborative Study to Evaluate the Proposed 1st WHO International Standard for Epstein-Barr Virus (EBV) for Nucleic Acid Amplification Technology (NAT)-Based Assays

A. Heath, P. Minor, Dianna E. Wilkinson, 2011 .

Commutability of the World Health Organization International Standard for Human Cytomegalovirus: Standard or Assay

P. Minor, N. Almond, C. Morris, 2016, Journal of Clinical Microbiology.

Standardisation of nucleic acid amplification assays used in clinical diagnostics: a report of the first meeting of the SoGAT Clinical Diagnostics Working Group.

P. Minor, J. Fryer, 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Creation of an antigenic site in poliovirus type 1 by assembly of 14 S subunits.

B. Rombaut, A. Mosser, R. Rueckert, 1990, Virology.

Standards for the assay of Creutzfeldt-Jakob disease specimens.

J. Newham, C. Bergeron, M. Vey, 2004, The Journal of general virology.

Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins

S. Beddows, G. Mattiuzzo, P. Minor, 2014, Vaccine.

P. Minor, N. Berry, S. M. Gilliland, 2013, Biologicals : journal of the International Association of Biological Standardization.

Laboratory tests for mumps vaccines.

P. Minor, 1997, Biologicals : journal of the International Association of Biological Standardization.

Antigenic structure of picornaviruses.

P. Minor, 1990, Current topics in microbiology and immunology.

Expert Review on Poliovirus Immunity and Transmission

M. Pallansch, K. Thompson, R. D. Duintjer Tebbens, 2013, Risk analysis : an official publication of the Society for Risk Analysis.

In vitro and in vivo growth alter the population dynamic and properties of a Jeryl Lynn mumps vaccine

P. Minor, E. Vítková, J. Wheeler, 2015, Vaccine.

Genetic and antigenic variation in type 3 polioviruses: characterization of strains by monoclonal antibodies and T1 oligonucleotide mapping.

G. Schild, P. Minor, A. John, 1982, The Journal of general virology.

The complete nucleotide sequence of coxsackievirus B4 and its comparison to other members of the Picornaviridae.

P. Minor, J. Almond, O. Jenkins, 1987, The Journal of general virology.

Immunogenicity and antigenicity of chimeric picornaviruses which express hepatitis A virus (HAV) peptide sequences: evidence for a neutralization domain near the amino terminus of VP1 of HAV.

S. Lemon, W. Barclay, P. Minor, 1992, Virology.

Hepatitis A virus concentrations in immunoglobulin preparations

R. Thorpe, P. Minor, David Wood, 1991, The Lancet.

Comparison of the nucleotide and deduced amino acid sequences of the envelope protein genes of the wild-type French viscerotropic strain of yellow fever virus and the live vaccine strain, French neurotropic vaccine, derived from it.

A. Barrett, P. Minor, J. Whitby, 1993, Virology.

Polio eradication, cessation of vaccination and re-emergence of disease

P. Minor, Philip D. Minor, 2004, Nature Reviews Microbiology.

WHO collaborative study on the use of monoclonal antibodies for the intratypic differentiation of poliovirus strains.

G. Schild, P. Minor, D. Magrath, 1986, Bulletin of the World Health Organization.

RT‐PCR based diagnosis and molecular characterisation of mumps viruses derived from clinical specimens collected during the 1996 mumps outbreak in Portugal

P. Minor, M. Afzal, M. Cordeiro, 1997, Journal of medical virology.

The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates.

A. Heath, P. Minor, M. Afzal, 1993, The Journal of general virology.

Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera.

R. Meloen, G. Dunn, P. Minor, 1993, The Journal of general virology.

Minimise transmission risk of CJD and vCJD in healthcare settings. Report on the Prevention of CJD and vCJD by Advisory Committee on Dangerous Pathogens' Transmission Spongiform Encephalopathy (ACDP TSE) Subgroup.

D. Jeffries, R. Cumming, A. Fraise, 2015 .

Detection and growth kinetics of SV40 preparations with different enhancer element copy number.

G. Dunn, P. Minor, P. Pipkin, 2001, Vaccine.

Molecular diagnostics: harmonization through reference materials, documentary standards and proficiency testing

Philip Minor, Lisa V Kalman, M. Holden, 2011, Expert review of molecular diagnostics.

Assay of humoral immunity to mumps virus.

A. Heath, P. Minor, P. Pipkin, 1999, Journal of virological methods.

WHO working group on the quality, safety and efficacy of japanese encephalitis vaccines (live attenuated) for human use, Bangkok, Thailand, 21-23 February 2012.

P. Minor, D. Trent, T. Jivapaisarnpong, 2013, Biologicals : journal of the International Association of Biological Standardization.

WHO informal consultation on scientific basis for regulatory evaluation of candidate human vaccines from plants, Geneva, Switzerland, 24-25 January 2005.

P. Minor, J. W. van der Laan, R. Mahoney, 2006, Vaccine.

Further evidence of the absence of measles virus genome sequence in full thickness intestinal specimens from patients with Crohn's disease

P. Minor, M. Afzal, S. Ghosh, 2000, Journal of medical virology.

Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates.

S. R. Pollard, R. Skuce, P. Minor, 1993, Virology.

Absence of detectable measles virus genome sequence in blood of autistic children who have had their MMR vaccination during the routine childhood immunization schedule of UK

A. O'hare, P. Minor, L. Ozoemena, 2006, Journal of medical virology.

Potency assay design for adjuvanted recombinant proteins as malaria vaccines.

P. Minor, A. Saul, B. Giersing, 2006, Vaccine.

Antibody to hepatitis C virus in plasma pools

R. Thorpe, P. Minor, P. Pipkin, 1990, The Lancet.

WHO collaborative study to assess the suitability of the 1st International Standard and the 1st International Reference Panel for antibodies to Ebola virus. WHO Expert Committee On Biological Standardization

P. Rijal, G. Mattiuzzo, M. Hassall, 2017 .

Recognition of poliovirus/HIV chimaeras by antisera from individuals with HIV infection

I. Weller, P. Minor, J. Almond, 1991, AIDS.

Growth and characterization of poliovirus antigen chimeras.

P. Minor, D. Evans, 1992, Methods in molecular biology.

Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies.

G. Schild, P. Minor, D. Magrath, 1984, The Journal of general virology.

Nucleic acid sequence of the region of the genome encoding capsid protein VP1 of neurovirulent and attenuated type 3 polioviruses.

A. Cann, R. Mountford, G. Schild, 1983, European journal of biochemistry.

Significance of contamination with viruses of cell lines used in the production of biological medicinal products

P. Minor, 1994 .

The challenge for the public health system.

P. Minor, 2004, Contributions to microbiology.

The nucleotide sequence of a type 3 poliovirus isolated during a recent outbreak of poliomyelitis in Finland.

G. Schild, D. Evans, P. Minor, 1986, The Journal of general virology.

Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus.

S. Watowich, A. Barrett, L. Dunster, 1999, Virology.

Reverse transcriptase activity in vaccines derived from chick cells.

P. Minor, J. Robertson, 1996, Biologicals : journal of the International Association of Biological Standardization.

Developing biological standards for vaccine evaluation

G. Mattiuzzo, P. Minor, S. Efstathiou, 2017 .

Studies on the loss of infectivity of live type 3 poliovaccine on storage.

P. Minor, P. Pipkin, 1998, Biologicals (Print).

Comparative evaluation of measles virus specific TaqMan PCR and conventional PCR using synthetic and natural RNA templates

P. Minor, M. Afzal, L. C. Ozoemena, 2004, Journal of medical virology.

Vaccines and variant CJD.

P. Minor, R. Will, D. Salisbury, 2000, Vaccine.

WHO Working Group on technical specifications for manufacture and evaluation of dengue vaccines, Geneva, Switzerland, 11-12 May 2009.

J. Hombach, P. Minor, I. Knezevic, 2010, Vaccine.

Absence of detectable measles virus genome sequence in inflammatory bowel disease tissues and peripheral blood lymphocytes

A. Ferguson, P. Minor, J. Begley, 1998, Journal of medical virology.

Changes in Population Dynamics during Long-Term Evolution of Sabin Type 1 Poliovirus in an Immunodeficient Patient

Javier Martin, G. Dunn, P. Minor, 2008, Journal of Virology.

Meeting on the acceptance criteria for virus validation studies. Langen 10 November, 1994.

P. Minor, 1995, Biologicals : journal of the International Association of Biological Standardization.

A sensitive PCR method for detecting HCV RNA in plasma pools, blood products, and single donations

J. Saldanha, P. Minor, P. Minor, 1994, Journal of medical virology.

Absence of detectable measles virus genome sequence in inflammatory bowel disease tissues and peripheral blood lymphocytes

A. Ferguson, P. Minor, J. Begley, 1998, Journal of medical virology.

Antigenic characterization of poliovirus type 3 using monoclonal antibodies.

G. Schild, P. Minor, D. Magrath, 1984, Reviews of infectious diseases.

Poliovirus vaccination: current understanding of poliovirus interactions in humans and implications for the eradication of poliomyelitis

P. Minor, 1999, Expert Reviews in Molecular Medicine.

Antigenic structure of poliovirus.

P. Minor, 1986, Microbiological sciences.

The complete nucleotide sequence of enterovirus type 70: relationships with other members of the picornaviridae.

M. Ryan, P. Minor, J. Almond, 1990, The Journal of general virology.

Polio vaccines and the cessation of vaccination

P. Minor, 2003, Expert review of vaccines.

New Strains Intended for the Production of Inactivated Polio Vaccine at Low-Containment After Eradication

P. Minor, A. Macadam, J. Burlison, 2015, PLoS pathogens.

A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating

G. Schild, M. Skinner, G. Dunn, 1992, Journal of virology.

Differences in antigenic structure of inactivated poliovaccines made from Sabin live-attenuated and wild-type poliovirus strains: impact on vaccine potency assays.

Javier Martin, P. Minor, G. Cooper, 2019, The Journal of infectious diseases.

WHO expert committee on biological standardization. Thirty-seventh report.

I. Osipova, G. Unger, H. Meyer, 1987, World Health Organization technical report series.

The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland.

Javier Martin, P. Minor, G. Ferguson, 2000, Virology.

Summary Report of a Meeting on the Estimation of the Potency of Inactivated Poliovaccine

P. Minor, 1990, Biologicals (Print).

WHO informal consultation on the application of molecular methods to assure the quality, safety and efficacy of vaccines, Geneva, Switzerland, 7-8 April 2005.

K. Peden, P. Minor, D. Wood, 2007, Biologicals (Print).

Mumps viruses and mumps, measles, and rubella vaccine.

P. Minor, T. Forsey, 1989, British medical journal.

Application of deglycosylation to SDS PAGE analysis improves calibration of influenza antigen standards.

M. Hamill, O. Engelhardt, S. Itamura, 2012, Biologicals : journal of the International Association of Biological Standardization.

Poliovirus type 3: molecular cloning of the genome and nucleotide sequence of the region encoding the protease and polymerase proteins.

A. Cann, R. Mountford, G. Schild, 1983, Nucleic acids research.

The sequence of the coxsackievirus A21 polymerase gene indicates a remarkably close relationship to the polioviruses

P. Minor, G. Stanway, P. Hughes, 2005, Archives of Virology.

Use of human diploid cells in vaccine production.

P. Minor, D. Wood, D J Wood, 1990, Biologicals : journal of the International Association of Biological Standardization.

Assessment of the ferret as an in vivo model for mumps virus infection.

P. Minor, S. M. Gilliland, S. Schepelmann, 2013, The Journal of general virology.

Inactivated influenza vaccines prepared in cell culture. Summary and recommendations.

P. Minor, 1999, Developments in biological standardization.

International reference preparations for standardization of biological medicinal products

P. Minor, 2014, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

A global regulatory science agenda for vaccines.

K. Cichutek, A. Kato, Xuguang Li, 2013, Vaccine.

A collaborative study to establish the 3rd WHO International Standard for hepatitis B virus for nucleic acid amplification techniques.

A. Heath, P. Minor, Dianna E. Wilkinson, 2017, Biologicals : journal of the International Association of Biological Standardization.

A. Nomoto, B. Mahon, P. Minor, 1995, The Journal of experimental medicine.

Polio vaccines and the eradication of poliomyelitis

Philip D Minor, P. Minor, 2012, The Lancet.